Comment & Sign-on Letters

LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.

Access to Care & Reimbursement

Support for legislation that would improve patients’ access to care

LUNGevity Foundation Comment Letter to CMS on the Laboratory Date of Service/ 14-Day Rule Policy (September 13, 2019)

MAPRx Coalition Letter to Senate Finance Committee (July 25, 2019)

Community sign-on letter in response to Office of Management and Budget’s (OMB) request for comments on changes to calculations for adjusting the official poverty measure (OPM) (June 21, 2019)

LUNGevity comments on the Draft MolDX Local Coverage Determination for Guardant360® Plasma‐Based Comprehensive Genomic Profiling in Solid Tumors (DL38043) (June 20, 2019)

LUNGevity comments on the ICER 2020 Value Assessment Framework (June 10, 2019)

MapRx comment letter on out-of-pocket cap to Ways and Means and Energy and Commerce Committees (June 6, 2019)

CLC sign-on letter on out-of-pocket cap to Ways and Means and Energy and Commerce Committees (June 6, 2019)

LUNGevity Comments on CMS’s National Coverage Analysis for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (May 29, 2019)

Community Letter in Support of The Women and Lung Cancer Act of 2019 (May 1, 2019)

MapRx Comment Letter on Proposed Removal of Safe Harbor for Rebates (April 8, 2019)

Coalition Letter in Support of State Medicaid Coverage for Lung Cancer Screening (March 19, 2019)

Cancer Leadership Council Letter to Senator Alexander re: Health Care Costs (March 1, 2019)

Cancer Leadership Council Letter to CMS on the Proposed Rule to Modernize Medicare Part D and Medicare Advantage (January 25, 2019)

CSC Letter to CMS on the Proposed Rule to Modernize Medicare Part D and Medicare Advantage (January 25, 2019)

Partnership for Part D Access Letter to CMS on the Proposed Rule to Modernize Medicare Part D and Medicare Advantage (January 25, 2019)

Cancer Leadership Council letter to HHS on the International Pricing Index (IPI) model for Medicare Part B drugs (December 31, 2018)

CSC comment letter to HHS on the International Pricing Index (IPI) model for Medicare Part B drugs (December 31, 2018)

Cancer Leadership Council Statement on Affordable Care Act Ruling (December 18, 2018)

Cancer Leadership Council comments on drug pricing transparency proposal (December 17, 2018)

LUNGevity Comments on Inivata Liquid LCD (November 15, 2018)

Letter to House & Senate – Part B MA Step Therapy (September 26, 2018)

ASP Medicare Part B Step Therapy Letter (September 12, 2018)

Patient Group Letter to CVS (September 12, 2018)

Patient & Provider Comments to CMS on DME Oxygen (September 6, 2018)

LUNGevity NGS Comments to Oregon HERC (August 13, 2018)

PAN Patient Community HHS Blueprint Letter (July 16, 2018)

REAP Coalition HHS Blueprint Letter (July 16, 2018)

CSC HHS Blueprint Letter (July 15, 2018)

LUNGevity Comments on Guardant360 LCD – May 2018 (May 9, 2018)

Cancer Care Planning and Communication Act, H.R. 5160 (March 14, 2018)

Right to Try Coalition Letter (House) (March 12, 2018)

Right to Try (S.204 & H.R. 878) (February 6, 2018)

LUNGevity NGS National Coverage Determination Comments to CMS (January 17, 2018)

LUNGevity CMMI 2017 RFI Comments (November 20, 2017)

REAP Coalition CMMI 2017 RFI (November 20, 2017)

Veterans Affairs ICER Letter (November 13, 2017)

MassHealth 1115 Waiver Letter 2017 (October 18, 2017)

340B Drug Discount Program (September 27, 2017)

Sign-On HOPPS CY 2018 Laboratory Date of Service Policy (14 Day Rule) Comments to CMS (September 11, 2017)

LUNGevity HOPPS CY 2018 Laboratory Date of Service Policy (14 Day Rule) Comments to CMS (September 7, 2017)

Guardant360 LCD 2017 (July 19, 2017)

Medicaid Expansion and Per Capita Caps (June 15, 2017)

Letter on Patient Protection and Affordable Care Act; Market Stabilization (March 7, 2017)

Regence reimbursement policy letter (February 14, 2017)

Letter to House (February 6, 2017)

Letter to Senate (February 6, 2017)

Joint letter to Congress (February 2, 2017)

Comment on ICER blog

Letter on ICER draft document for NSCLC (September 15, 2016)

Partnership to Improve Patient Care ICER letter (September 12, 2016)

Letter to CMS supporting screening (October 8, 2014)

Food and Drug Administration (FDA)

Diagnostics Testing Regulation

Federal Research Funding

21st Century Cures

Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation

Letter to House and Senate (November 16, 2016)

print